Monopar Therapeutics
MNPR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645469
In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 7 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:49 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 27, 2026 | Mar 31, 2025 | Mar 28, 2024 | Mar 23, 2023 | Mar 24, 2022 |
| Revenue | $0 | $0 | – | – | – |
| Operating expenses | $16.7M | $16.2M | $8.83M | $10.5M | $9.13M |
| Research and development | $9.90M | $13.0M | $5.60M | $7.59M | $6.49M |
| Selling, general and administrative | $6.80M | $3.16M | $3.23M | $2.95M | $2.63M |
| Operating income | -$16.7M | -$16.2M | -$8.83M | -$10.5M | -$9.13M |
| Income tax | $800 | $800 | $800 | $0 | $0 |
| Net income | -$13.7M | -$15.6M | -$8.40M | -$10.5M | -$9.10M |
| EPS, basic | $-1.85 | $-4.11 | $-0.61 | – | – |
| Weighted shares, basic | 7.41M | 3.79M | 13.8M | 12.7M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 27, 2026 | Mar 31, 2025 | Mar 28, 2024 | Mar 23, 2023 | Mar 24, 2022 |
| Cash and equivalents | $61.8M | $45.8M | $7.27M | $8.19M | $20.3M |
| Total current assets | $140.5M | $60.3M | $7.33M | $13.2M | $20.5M |
| Total assets | $140.7M | $60.3M | $7.35M | $13.2M | $20.5M |
| Total current liabilities | $2.74M | – | $1.76M | $3.13M | – |
| Total liabilities | $2.89M | $5.25M | $1.76M | $3.14M | $1.58M |
| Shareholders' equity | $137.8M | $55.0M | $5.59M | $10.1M | $18.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 27, 2026 | Mar 31, 2025 | Mar 28, 2024 | Mar 23, 2023 | Mar 24, 2022 |
| Operating cash flow | -$12.2M | -$6.40M | -$7.86M | -$7.23M | $7.32M |
| Stock-based compensation | $4.84M | $1.14M | $1.90M | $1.64M | $1.47M |
| Share buybacks | $35.0M | – | – | – | – |
| Investing cash flow | -$63.5M | -$14.3M | $4.93M | -$4.92M | – |
| Financing cash flow | $91.6M | $59.3M | $2.03M | $32.9K | $10.9M |
| Net change in cash | $16.0M | $38.6M | -$920.1K | -$12.1M | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Jul 31, 2026 | 6.71M | +8.8% | SEC |
| Apr 30, 2026 | 6.70M | +9.5% | SEC |
| Mar 17, 2026 | 6.69M | +9.5% | SEC |
| Oct 31, 2025 | 6.68M | +26.6% | SEC |
| Jul 31, 2025 | 6.17M | −64.9% | SEC |
| Apr 30, 2025 | 6.12M | −65.0% | SEC |
| Mar 14, 2025 | 6.11M | −65.0% | SEC |
| Oct 31, 2024 | 5.28M | −64.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-5 in Q3 2024.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.